Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sotalol Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : $69.3 million
Deal Type : Public Offering
Hyloris Pharmaceuticals Raises Approximately EUR 61.81 Million in Successful Initial Public Offering
Details :
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 26, 2020
Lead Product(s) : Sotalol Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : $69.3 million
Deal Type : Public Offering